ANI Pharmaceuticals, Inc.
ANIP
$75.42
-$1.12-1.46%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 3.28% | 211.35% | -45.48% | 252.60% | 57.48% |
| Total Depreciation and Amortization | -0.08% | -2.79% | 1.70% | 1.29% | 43.51% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -43.70% | 63.19% | 257.76% | -159.02% | -33.79% |
| Change in Net Operating Assets | -50.56% | -149.22% | 2,626.56% | 127.79% | -157.43% |
| Cash from Operations | -31.07% | -41.89% | 116.66% | 120.62% | 27.14% |
| Capital Expenditure | 79.62% | -52.04% | -62.25% | -3.34% | 50.25% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 97.91% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -165.00% | 97.93% | 83.34% | -20,100.00% | 86.37% |
| Cash from Investing | 77.24% | 10.80% | 65.19% | -85.81% | 97.32% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -100.05% | 0.00% | 0.00% | 0.00% | 99.31% |
| Issuance of Common Stock | -99.61% | 688.24% | -50.99% | 49.06% | 42.62% |
| Repurchase of Common Stock | 41.48% | -89.47% | 94.49% | -3,045.60% | 53.24% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 100.00% | 15.48% | -0.25% | 0.00% | 0.00% |
| Other Financing Activities | 100.00% | -- | -- | -- | 93.34% |
| Cash from Financing | -173.07% | 463.19% | 82.36% | -101.87% | -101.69% |
| Foreign Exchange rate Adjustments | -334.90% | -31.51% | 383.16% | 24.81% | -426.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -48.73% | -34.10% | 1,275.90% | 4,117.89% | 99.87% |